Klivira
Request demo

Optimizing Vyepti Prior Authorization for Dermatology Practices

Dermatology practices navigate a complex prior authorization landscape, encompassing specialty biologics and procedures, alongside managing prior authorizations for high-volume medications like Vyepti.

Efficiently managing prior authorizations is critical for revenue cycle integrity and patient access in dermatology. From complex biologics for chronic conditions to specific procedures and diverse specialty medications, the administrative burden can impact practice efficiency and patient care. Klivira provides a robust solution designed to streamline these diverse PA requirements.

The Prior Authorization Landscape in Dermatology

Dermatology practices routinely encounter prior authorization requirements for a wide array of treatments, including advanced biologics for conditions like psoriasis and atopic dermatitis, as well as specialized surgical procedures. This complexity necessitates a precise and efficient approach to PA management to ensure timely patient access and optimize revenue cycles.

Key Prior Authorization Categories in Dermatology

  • Biologics for psoriasis, psoriatic arthritis, and atopic dermatitis (e.g., TNF, IL-17, IL-23, JAK inhibitors)
  • Hidradenitis suppurativa biologics
  • Mohs micrographic surgery for non-melanoma skin cancers
  • Advanced skin cancer treatments, including immunotherapy and targeted therapies
  • Phototherapy, particularly for home-administered regimens

Navigating High-Volume Prior Authorizations for Diverse Medications

While dermatology practices primarily focus on skin-specific treatments, they often manage prior authorizations for a broader range of medications that patients may be prescribed, including high-volume PA targets like Vyepti. Processing these diverse drug PAs efficiently, alongside specialty dermatology treatments, requires a versatile and automated system.

Essential Documentation for Dermatology Prior Authorizations

  • Diagnosis documentation (e.g., PASI/BSA for psoriasis, EASI/SCORAD for atopic dermatitis)
  • Evidence of prior topical therapy and/or phototherapy trials
  • Documentation of prior conventional systemic therapy (e.g., methotrexate, cyclosporine) trial
  • TB and hepatitis screening results for pre-biologic initiation
  • Adherence to AAD Clinical Guidelines and NCCN for skin cancers, including Mohs Appropriate Use Criteria

Mitigating Common Prior Authorization Denials in Dermatology

Dermatology practices frequently face denials due to issues such as non-compliance with step therapy protocols, insufficient documentation of disease severity, or discrepancies with appropriate use criteria. Proactive identification and resolution of these common pitfalls are essential to minimize rework and accelerate approvals.

Typical Denial Reasons in Dermatology PA

  • Failure to document step therapy compliance for biologics (e.g., prior topical, phototherapy, conventional systemic trials)
  • Biosimilar substitution requirements not met for TNF inhibitors
  • Mohs Appropriate Use Criteria (AUC) mismatch for site or tumor type
  • Inadequate documentation of disease severity (missing PASI, EASI, BSA scores)
  • Gaps in pre-biologic screening (e.g., TB, hepatitis)

Klivira's Role in Streamlining Dermatology Prior Authorizations

Klivira's platform is engineered to address the specific workflow constraints and documentation demands of dermatology practices. By integrating with EMRs and payer portals, we automate the submission process, apply AAD guideline-aware logic for biologics, validate AUC for Mohs surgery, and manage periodic re-authorization cycles for chronic treatments, reducing administrative burden across all PA types, including those for high-volume drugs like Vyepti.

Frequently asked questions

How does Klivira handle the diverse range of prior authorizations in dermatology, from biologics to procedures?

Klivira's platform is designed for versatility, automating PA workflows for biologics, specialty drugs, and procedures like Mohs surgery. It leverages payer-specific rules and clinical guidelines, ensuring all diverse PA types common in dermatology are processed accurately and efficiently.

What specific dermatology guidelines does Klivira integrate for prior authorization?

Klivira incorporates logic aligned with AAD Clinical Guidelines for conditions like psoriasis and atopic dermatitis, as well as Appropriate Use Criteria for Mohs surgery. This ensures submitted prior authorizations meet established clinical benchmarks, reducing denial rates.

Can Klivira assist with prior authorizations for non-dermatology specific drugs that a dermatology practice might encounter, such as Vyepti?

Yes, Klivira's platform is built to manage prior authorizations for any medication or procedure requiring one, including high-volume drugs like Vyepti. Our system automates the submission and tracking process regardless of the drug's primary specialty, ensuring comprehensive PA coverage for your practice.

How does Klivira help dermatology practices manage periodic re-authorization for chronic biologic treatments?

Klivira's system includes automated reminders and workflow queues for periodic re-authorizations, which are common for chronic biologic treatments in dermatology. This ensures timely resubmissions, preventing lapses in patient care and ensuring continuous revenue.

What are common reasons for prior authorization denials in dermatology, and how does Klivira mitigate them?

Common denials stem from step therapy non-compliance, insufficient disease severity documentation, or Mohs AUC mismatches. Klivira mitigates these by guiding users through required documentation, validating against guidelines, and flagging potential issues pre-submission, significantly improving approval rates.

Related coverage

Other vyepti prior authorization by payer

Other vyepti prior authorization by specialty

Ready to automate prior auth for this drug?

See how Klivira automates prior authorizations for your team.

Request a demo